To recover your password please fill in your email address
Please fill in below form to create an account with us
Title: A Single arm, open label, phase II trial of alectinib in patients with advanced tumours harbouring ALK gene alterations detected by comprehensive genomic profiling.
|
Trial Summary: |
The aim of this ASPiRATION and MoST substudy to assess the clinical activity of of alectinib in adult patients with advanced cancers harbouring an ALK gene alteration. |
|
Supported By: |
|
|
Eligibility: |
Adult patients with advanced cancers harbouring ALK gene alterations identified using CGP. NSCLC patients with ALK gene alterations must be FISH-negative, i.e. not eligible for reimbursed ALK-targeted treatment. |
|
Registration ID: |
ACTRN12621000312842 |
|
Participation: |
National |
|
Status: |
Recruiting |
|
Activation date: |
11/05/2021 |
|
Chairs: |
Dr Malinda Itchins and Dr Frank Lin |
|
Contact: |